Arrowhead initiates Adipotide Phase 1 trial in obesity

Published on July 11, 2012 at 8:51 AM · 3 Comments

Arrowhead Research Corporation (NASDAQ: ARWR), a targeted therapeutics company, today announced that the first patient has been dosed in a Phase 1 clinical trial with Adipotide®, a new class of treatment for obesity. Adipotide, formerly known as Prohibitin-TP01, is a synthetic peptide that targets a protein on the surface of blood vessels supporting white adipose tissue (fat), disrupting the blood supply to fat cells and causing them to be reabsorbed and metabolized. Treatment has led to substantial weight loss, decreased food intake, and rapid metabolic changes with implications for Type II diabetes in multiple experimental animal models.    

The Phase 1 trial is designed to evaluate a single 28 day cycle of Adipotide in patients with castrate-resistant prostate cancer and no standard treatment options. The study is intended to identify a maximum tolerated dose, assess pharmacokinetics, measure the change in weight, and monitor disease progression, in addition to other secondary outcome measures. Fat tissue is known to produce substances that can promote prostate cancer growth. Investigators at the MD Anderson Cancer Center, who are conducting and bearing the costs of the clinical trial, also seek to learn if decreasing white fat, the type of fat associated with obesity, can slow the growth of prostate cancer.

Patients will receive Adipotide as an injection under the skin once daily for 28 days. Up to five dose levels will be tested with three participants enrolled at each dose level. The first group will receive the lowest dose and each new group will receive a higher dose level than the group before it, based on an evaluation of observed safety. This will continue until the highest dose of Adipotide with acceptable safety is found or all five dosing cohorts have been completed.

Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | Nederlands | Русский | Svenska | Polski
  1. Harry Stewart Harry Stewart United States says:

    Has any consideration been given to the treatment of OSA by the use of Adipotide therapy?  It is my understanding that a significant contributor to OSA, is an enlarged neck size (my case ~ 21in. circumferance).  I believe the large neck size contributes to OSA by the relaxation of tissue during sleep.  I'm not sure if or how fat cells play into this condition, but believe the possibility exists that any loss in neck size (especially excess fats cells) could contribute to improvements in OSA by less obstruction.
    Your thoughts?

  2. charles gazzari charles gazzari United States says:

    The 28 days for these animal experiments are over. What is the next step toward production for general consumption, and on what approximate time frame?

  3. Jean Jean United States says:

    How does a person volunteer to be included in a case study?

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment